Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 10/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3159978 | 0.80 | SIRT1 (0.46) | SIRT2SIRT1PARP1 | |
| SCHEMBL3173779 | 0.75 | PARP1 (0.44) | PARP1 | |
| SCHEMBL3168792 | 0.72 | JAK2 (0.50) | CSF1RJAK2JAK3 | |
| SCHEMBL4247074 | 0.71 | CSNK1A1 (0.45) | CSNK1A1TYRO3DYRK1BPARP1ADRA2A | |
| SCHEMBL3165470 | 0.71 | CHEK1 (0.40) | JAK2MAPK8GSK3B | |
| SCHEMBL5168511 | 0.71 | SIRT2 (0.42) | SIRT2SIRT1CSF1RDYRK1BJAK2 | |
| SCHEMBL3174985 | 0.70 | PARP1 (0.45) | PARP1 | |
| SCHEMBL4651184 | 0.70 | BCAT2 (0.41) | DYRK1BJAK2PARP1GSK3B | |
| SCHEMBL3170684 | 0.70 | MAP4K4 (0.36) | CSF1R | |
| SCHEMBL3174393 | 0.69 | CYP11B2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841504-B1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154915-A1 | Substituted biaryl compounds as factor XIa inhibitors | TFPI, F3, F12 | ITGB3 512/4885ITGAV 915/4885SIRT2 2856/4885 |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | ITGB3 512/4885ITGAV 915/4885SIRT2 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.